INmune Bio Stock Soars 11.4% on Positive Alzheimer's Trial Data

INmune Bio's stock surged 11.4% in pre-market trading on April 3, 2025, driven by significant developments in its clinical trials for Alzheimer's disease.

INmune Bio recently presented data from its MINDFuL trial at the AD/PD 2025 Conference in Vienna, Austria. The trial focuses on early Alzheimer's disease patients with confirmed biomarkers of inflammation, enrolling 208 participants diagnosed with either Mild Cognitive Impairment or mild Alzheimer's disease. The study aims to evaluate the efficacy of XPro, an experimental treatment, through weekly subcutaneous injections over 23 weeks. The primary endpoint is the change from baseline in cognitive scores, measured by the Early and Mild Alzheimer's Cognitive Composite.

Preliminary baseline data indicate that the trial has successfully enrolled a well-characterized cohort of early Alzheimer's disease patients with immune system dysfunction. Topline results from the MINDFuL trial are anticipated in June 2025, which could further influence investor sentiment and stock performance.